Disclosure of Payments to Healthcare Professionals

Our collaborations with healthcare professionals always aim to benefit patients, improve medical practices and patient care. 
Activities can range from clinical research to exchanges on how new medicines fit into patient pathway. 
We believe that a more open transparent relationship strengthens the basis for collaboration and is in the best interest of patients and all health stakeholders.
For this reason, we are committed to disclose our interactions with healthcare professionals and organizations through the Disclosure Code de l’EFPIA.

 

Austria

 Public disclosure  2018, 20192020

 

 

Belgium

 

Bulgaria

Public disclosure 2018, 20192020
 

 

Cyprus

Public disclosure 2018, 2019
No Transfer of Value in 2020

 

Czech Republic 

Public disclosure  2018, 2019

No Transfer of Value in 2020

 
Denmark

Public disclosure   2018, 20192020

 

Estonia

Public disclosure  2018
No Transfer of Value in 2019, 2020

 

Finland

Public disclosure 2018, 20192020
 

France

 

Germany

 

Greece
 
Greece PFD report 2018/Greece PFMS report 2018/ Pierre Fabre Greek Crossborder ToVs 2018

Greece PFD report 2019/Greece PFMS report 2019/ Pierre Fabre Greek Crossborder ToVs 2019

Report PFD 2020/ Report PFMS 2020/ Pierre Fabre Greek Crossborder ToVs 2020 / Pierre Fabre Corporate Greek Crossborder 2020

 

 

Hungary

Public disclosure 2019
No Transfer of Value in 2018, 2020

 

Italy

 

Ireland

 

Lithuania


No Transfer of Value in 2018, 2019, 2020
 

Malta

No Transfer of Value in 2018, 2019, 2020

 

Netherlands 

 

Norway

Public disclosure 2018, 2019, 2020

 

Poland

Public disclosure HCP   2018, 2019, 2020
Public disclosure  HCO  2018, 20192020
Public disclosure R&D 2018, 2019,  2020

 

Portugal

Romania

No Transfer of Value in 2018, 2019, 2020


Russia

 

Slovak republic

Public disclosure 2018, 20192020

 

Spain

Sweden

Public disclosure 2018, 20192020
 


Switzerland

Public disclosure  2018, 2019, 2020

 

Ukraine

Public disclosure  2018
No Transfer of Value in 2019, 2020
 

United Kingdom



 

DISCLOSURE METHODOLOGY PIERRE FABRE PHARMACEUTICALS TOV 2020

  • The publication provided through this section is made in accordance with the Company Self-Certification.
  • Following European legislation on data privacy, recipients of published transfers of value have a right to access and correct personal data concerning them, which is exercisable by e-mail: transparency.compliance@pierre-fabre.com